Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part II

Circulation

Volumn 104, Issue 20, 2001, Pages 2498-2502

  Shah, Prediman K ^a   Kaul, Sanjay ^a   Nilsson, Jan ^b   Cercek, Bojan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MALMÖ UNIVERSITY   (Sweden)

Author keywords

Apolipoproteins; Atherosclerosis; Lipoproteins

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; DISEASE ASSOCIATION; HEART FUNCTION; HEART PROTECTION; LIPOPROTEIN BLOOD LEVEL; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

EID: 0035856555     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4501.098468     Document Type: Review

References (80)

1. Structure and function of apolipoprotein A-I and high-density lipoprotein
2. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E- deficient mouse
3. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
4. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice
5. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice
6. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice
7. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles
8. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II
9. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV
10. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase
11. The yin and yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff Memorial Lecture
12. Is paraoxonase related to atherosclerosis?
13. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
14. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
15. The genetic mapping and gene structure of mouse paraoxonase/arylesterase
16. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
17. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
18. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis
19. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein
20. Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity
21. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
22. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants
23. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
24. Paraoxonase-gene polymorphisms associated with coronary heart disease: Support for the oxidative damage hypothesis?
25. Human serum paraoxonase
26. Paraoxonase and coronary heart disease
27. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase
28. The antiatherogenic role of high-density lipoprotein cholesterol
29. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
30. Does paraoxonase play a role in susceptibility to cardiovascular disease?
31. Atheroprotective mechanisms of HDL
32. Reverse cholesterol transport: Physiology and pharmacology
33. Apolipoprotein A-I-containing particles and reverse cholesterol transport: Evidence for connection between cholesterol efflux and atherosclerosis risk
34. Reverse cholesterol transport: A review of the process and its clinical implications
35. Molecular mechanisms of reverse cholesterol transport
36. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-1 and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport
37. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
38. Human apolipoproteins A-I and A-II in cell cholesterol efflux: Studies with transgenic mice
39. Very low high-density lipoproteins without coronary atherosclerosis
40. Milano apoprotein: Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family
41. Milano apoprotein: Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins
42. Milano carriers and transgenic mice
43. Milano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol
44. Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transport
45. Mechanistic studies of high-density lipoproteins
46. New perspectives on the management of low levels of high-density lipoprotein cholesterol
47. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
48. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
49. Statin-induced inhibition of Rho-signaling pathway activates PPAR∞ and induces HDL apoA-I
50. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
51. CETP and atherosclerosis
52. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
53. Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits
54. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice
55. Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice
56. Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor
57. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice
58. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty
59. Effects of intravenous infusion of lipid-free apo A-I in humans
60. Acute effects of intravenous infusion of ApoAI/phosphatidylcholine discs on plasma lipoproteins in humans
61. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans
62. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol
63. Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic alpha-helixes
64. Remodeling and shuttling: Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol
65. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools: Implications for the treatment of atherosclerosis
66. Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport
67. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
68. Gene therapy for atherosclerosis
69. Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus
70. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models
71. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor
72. The Tangier disease gene product ABC 1 controls the cellular apolipoprotein-mediated lipid removal pathway
73. Sterol dependent transcativation of the human ABC I promoter by liver X receptor/retinoid X receptor
74. ABC I gene expression and apo A-I mediated cholesterol efflux are regulated by LXR
75. Control of cellular cholesterol effiux by nuclear oxysterol receptor LXR alpha
76. Regulation of absorption and ABC I-mediated efflux of cholesterol by RXR heterodimers
77. A selective PPAR-δ agonist promotes reverse cholesterol transport
78. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of retinoid X receptor
79. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters
80. An absorbing study of cholesterol